The significant beat on the EPS estimate and the improvement from last year's losses are likely to be viewed positively by investors, potentially leading to a short-term uptick in BIOL's stock price. However, the slight miss on sales forecasts could temper some of the enthusiasm, hence the importance is not at the maximum.